年龄相关性黄斑变性患者的新冠发病率与严重程度:韩国全国性队列研究
该韩国全国性队列研究纳入2020年1月1日至5月15日期间接受SARS-CoV-2检测的≥40岁人群,采用倾向性评分匹配分析年龄相关性黄斑变性(AMD)与SARS-CoV-2感染易感性及重症结局的关联。匹配后,渗出性AMD与SARS-CoV-2感染易感性升高(aOR 1.50,95%CI 1.03-2.25)及COVID-19重症临床结局风险显著增加(aOR 2.26,95%CI 1.02-5.26)相关,但任何AMD及非渗出性AMD无此关联。
要点
- 渗出性AMD与SARS-CoV-2感染易感性升高相关(aOR 1.50,95%CI 1.03-2.25)。
- 渗出性AMD与COVID-19重症结局风险增加相关(aOR 2.26,95%CI 1.02-5.26)。
- 任何AMD及非渗出性AMD与SARS-CoV-2感染或重症结局无显著关联。
核心结论
- 在韩国全国性队列中,渗出性AMD患者对SARS-CoV-2感染的易感性及COVID-19重症临床结局风险增加。
研究设计与样本
- 韩国全国性基于人群的队列研究,采用倾向性评分匹配。
- 数据来源于韩国健康保险审查与评估服务,纳入2020年1月1日至5月15日期间接受SARS-CoV-2检测的≥40岁所有患者(排除自费检测)。
主要发现
- 未匹配队列共135,435例接受SARS-CoV-2检测的患者,其中4,531例(3.3%)检测阳性,5,493例(4.1%)患有AMD。
- 倾向性评分匹配后,渗出性AMD与SARS-CoV-2感染易感性增加相关(aOR 1.50;95%CI 1.03-2.25)。
- 倾向性评分匹配后,渗出性AMD与COVID-19重症临床结局风险显著增加相关(aOR 2.26;95%CI 1.02-5.26)。
- 任何AMD及非渗出性AMD与SARS-CoV-2感染易感性或COVID-19重症结局无显著关联。
临床怎么用
- 临床医生应意识到渗出性AMD患者对SARS-CoV-2感染易感性及COVID-19重症临床结局风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the potential association between age-related macular degeneration (AMD), a representative chronic age-related degenerative disease of the retina associated with inflammation and aging, and susceptibility to SARS-CoV-2 infection and severe COVID-19 outcomes. DESIGN: Nationwide cohort study with propensity-score matching. METHODS: A population-based nationwide cohort in Korea was examined. Data were obtained from the Health Insurance Review & Assessment Service of Korea, including all patients aged ≥40 years who underwent SARS-CoV-2 testing in South Korea between January 1, 2020 and May 15, 2020 (excluding self-referral). The primary outcome was SARS-CoV-2 test positivity and the secondary outcome was severe clinical outcome of COVID-19. RESULTS: The unmatched cohort consisted of 135,435 patients who were tested for SARS-CoV-2: 4531 patients (3.3%) tested positive for SARS-CoV-2 and 5493 (4.1%) had AMD. After propensity score matching, exudative AMD was associated with an increased likelihood of susceptibility to SARS-CoV-2 infection (adjusted odds ratio [aOR], 1.50; 95% confidence interval [CI], 1.03-2.25), and a considerably greater risk of severe clinical outcomes of COVID-19 (aOR, 2.26; 95% CI, 1.02-5.26), but not any AMD and non-exudative AMD. CONCLUSIONS: In a Korean nationwide cohort, data suggest that clinicians should be aware of the greater risk of susceptibility to severe clinical outcomes of COVID-19 in patients with exudative AMD. These findings provide an improved understanding of the relationship between the pathogenesis of COVID-19 and chronic neurological disorders.
引用
- Yang JM, Moon SY, Lee JY, et al. COVID-19 Morbidity and Severity in Patients With Age-Related Macular Degeneration: A Korean Nationwide Cohort Study. Am J Ophthalmol. 2021. PMID: 34102151. doi:10.1016/j.ajo.2021.05.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。